You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameErlotinib
Accession NumberDB00530  (APRD00951)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionErlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. Similar to gefitinib, erlotinib specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase. It binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. Erlotinib has recently been shown to be a potent inhibitor of JAK2V617F activity. JAK2V617F is a mutant of tyrosine kinase JAK2, is found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. The study suggests that erlotinib may be used for treatment of JAK2V617F-positive PV and other myeloproliferative disorders.
Structure
Thumb
Synonyms
[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Erlotinib
OSI-774
External Identifiers
  • CP358774
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PMS-erlotinibTablet150 mgOralPharmascience Inc2016-07-28Not applicableCanada
PMS-erlotinibTablet100 mgOralPharmascience Inc2016-07-28Not applicableCanada
TarcevaTablet25 mg/1OralPhysicians Total Care, Inc.2005-07-01Not applicableUs
TarcevaTablet25 mg/1OralGenentech, Inc.2005-04-30Not applicableUs
TarcevaTablet25 mgOralHoffmann La Roche Limited2007-01-05Not applicableCanada
TarcevaTablet150 mg/1OralPhysicians Total Care, Inc.2005-10-13Not applicableUs
TarcevaTablet100 mg/1OralGenentech, Inc.2005-04-30Not applicableUs
TarcevaTablet, film coated25 mgOralRoche Registration Limited2005-09-19Not applicableEu
TarcevaTablet100 mgOralHoffmann La Roche Limited2005-07-19Not applicableCanada
TarcevaTablet100 mg/1OralPhysicians Total Care, Inc.2005-11-21Not applicableUs
TarcevaTablet150 mg/1OralGenentech, Inc.2005-04-30Not applicableUs
TarcevaTablet, film coated100 mgOralRoche Registration Limited2005-09-19Not applicableEu
TarcevaTablet150 mgOralHoffmann La Roche Limited2005-07-19Not applicableCanada
TarcevaTablet100 mg/1OralAvera Mc Kennan Hospital2015-04-01Not applicableUs
TarcevaTablet, film coated150 mgOralRoche Registration Limited2005-09-19Not applicableEu
Teva-erlotinibTablet25 mgOralTeva Canada Limited2014-12-08Not applicableCanada
Teva-erlotinibTablet100 mgOralTeva Canada Limited2014-12-08Not applicableCanada
Teva-erlotinibTablet150 mgOralTeva Canada Limited2014-12-08Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Erlotinib Hydrochloride
183319-69-9
Thumb
  • InChI Key: GTTBEUCJPZQMDZ-UHFFFAOYSA-N
  • Monoisotopic Mass: 429.145533978
  • Average Mass: 429.897
DBSALT000064
Categories
UNIIJ4T82NDH7E
CAS number183321-74-6
WeightAverage: 393.4357
Monoisotopic: 393.168856239
Chemical FormulaC22H23N3O4
InChI KeyAAKJLRGGTJKAMG-UHFFFAOYSA-N
InChI
InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)
IUPAC Name
N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
SMILES
COCCOC1=C(OCCOC)C=C2C(NC3=CC=CC(=C3)C#C)=NC=NC2=C1
Pharmacology
IndicationFor the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Also for use, in combination with gemcitabine, as the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
Structured Indications
PharmacodynamicsNot Available
Mechanism of actionThe mechanism of clinical antitumor action of erlotinib is not fully characterized. Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized. EGFR is expressed on the cell surface of normal cells and cancer cells.
TargetKindPharmacological actionActionsOrganismUniProt ID
Epidermal growth factor receptorProteinyes
antagonist
HumanP00533 details
Nuclear receptor subfamily 1 group I member 2Proteinyes
agonist
HumanO75469 details
Related Articles
AbsorptionErlotinib is about 60% absorbed after oral administration and its bioavailability is substantially increased by food to almost 100%. Peak plasma levels occur 4 hours after dosing. The solubility of erlotinib is pH dependent. Solubility decreases pH increases. Smoking also decrease the exposure of erlotinib.
Volume of distribution

Apparent volume of distribution = 232 L

Protein binding93% protein bound to albumin and alpha-1 acid glycoprotein (AAG)
Metabolism

Metabolism occurs in the liver. In vitro assays of cytochrome P450 metabolism showed that erlotinib is metabolized primarily by CYP3A4 and to a lesser extent by CYP1A2, and the extrahepatic isoform CYP1A1.

Route of eliminationFollowing a 100 mg oral dose, 91% of the dose was recovered in which 83% was in feces (1% of the dose as unchanged parent compound) and 8% in urine (0.3% of the dose as unchanged parent compound).
Half lifeMedian half-life of 36.2 hours.
Clearance

Smokers have a 24% higher rate of erlotinib clearance.

ToxicitySymptoms of overdose include diarrhea, rash, and liver transaminase elevation. The most common adverse reactions (>50%) in NSCLC are rash, diarrhea, anorexia and fatigue. The most common adverse reactions (>50%) in pancreatic cancer are fatigue, rash, nausea and anorexia.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Erlotinib Action PathwayDrug actionSMP00472
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Epidermal growth factor receptor
Gene symbol: EGFR
UniProt: P00533
Not AvailableG719A/C OR (L858R and L861Q)Not AvailableAssociated with enhanced activation of the EGFR tyrosine kinase in patients with non-small cell lung cancer (NSCLC) recieving tyrosine kinase inhibitor therapy.15118073
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Erlotinib can be increased when it is combined with Abiraterone.Approved
AcetaminophenThe serum concentration of Erlotinib can be increased when it is combined with Acetaminophen.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Erlotinib.Approved
AfatinibThe serum concentration of Erlotinib can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Erlotinib can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Erlotinib can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Erlotinib can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Erlotinib can be increased when it is combined with Alfentanil.Approved, Illicit
Aluminum hydroxideThe serum concentration of Erlotinib can be decreased when it is combined with Aluminum hydroxide.Approved
Aluminum phosphateThe serum concentration of Erlotinib can be decreased when it is combined with Aluminum phosphate.Approved
AmantadineThe serum concentration of Erlotinib can be increased when it is combined with Amantadine.Approved
Aminohippuric acidThe serum concentration of Erlotinib can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe serum concentration of Erlotinib can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Erlotinib can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Erlotinib can be increased when it is combined with Amlodipine.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Erlotinib.Approved
AmprenavirThe serum concentration of Erlotinib can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Erlotinib can be increased when it is combined with Amsacrine.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Erlotinib.Investigational
AprepitantThe serum concentration of Erlotinib can be increased when it is combined with Aprepitant.Approved, Investigational
ArtemetherThe metabolism of Erlotinib can be decreased when combined with Artemether.Approved
AsenapineThe serum concentration of Erlotinib can be decreased when it is combined with Asenapine.Approved
AstemizoleThe serum concentration of Erlotinib can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Erlotinib can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Erlotinib can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Erlotinib can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Erlotinib can be increased when it is combined with Atorvastatin.Approved
AzelastineThe serum concentration of Erlotinib can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Erlotinib can be increased when it is combined with Azithromycin.Approved
BenzocaineThe serum concentration of Erlotinib can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Erlotinib can be increased when it is combined with Bepridil.Approved, Withdrawn
BetaxololThe metabolism of Erlotinib can be decreased when combined with Betaxolol.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Erlotinib.Approved, Investigational
BexaroteneThe serum concentration of Erlotinib can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe serum concentration of Erlotinib can be increased when it is combined with Biperiden.Approved
Bismuth SubcitrateThe serum concentration of Erlotinib can be decreased when it is combined with Bismuth Subcitrate.Approved
BoceprevirThe serum concentration of Erlotinib can be increased when it is combined with Boceprevir.Approved
BortezomibThe metabolism of Erlotinib can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Erlotinib can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Erlotinib can be increased when it is combined with Bosutinib.Approved
BromocriptineThe serum concentration of Erlotinib can be increased when it is combined with Bromocriptine.Approved, Investigational
BuprenorphineThe serum concentration of Erlotinib can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Erlotinib can be decreased when combined with Bupropion.Approved
BuspironeThe serum concentration of Erlotinib can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Erlotinib.Approved
CaffeineThe serum concentration of Erlotinib can be increased when it is combined with Caffeine.Approved
Calcium carbonateThe serum concentration of Erlotinib can be decreased when it is combined with Calcium carbonate.Approved
CanagliflozinThe serum concentration of Erlotinib can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Erlotinib can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Erlotinib can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Erlotinib can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarvedilolThe serum concentration of Erlotinib can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Erlotinib can be increased when it is combined with Caspofungin.Approved
CelecoxibThe metabolism of Erlotinib can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Erlotinib can be increased when it is combined with Ceritinib.Approved
ChloroquineThe serum concentration of Erlotinib can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Erlotinib can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Erlotinib can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Erlotinib can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholecalciferolThe metabolism of Erlotinib can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Erlotinib can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Erlotinib can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Erlotinib can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Erlotinib can be decreased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Erlotinib can be decreased when combined with Cinacalcet.Approved
CiprofloxacinThe serum concentration of Erlotinib can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Erlotinib can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Erlotinib can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Erlotinib can be decreased when combined with Clemastine.Approved
ClobazamThe metabolism of Erlotinib can be decreased when combined with Clobazam.Approved, Illicit
ClofazimineThe serum concentration of Erlotinib can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Erlotinib can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClopidogrelThe metabolism of Erlotinib can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe metabolism of Erlotinib can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Erlotinib can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Erlotinib can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Erlotinib can be decreased when combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Erlotinib can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Erlotinib can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Erlotinib can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Erlotinib can be decreased when combined with Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Erlotinib.Approved, Investigational
CyclosporineThe metabolism of Erlotinib can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Erlotinib can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Erlotinib can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Erlotinib can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Erlotinib can be increased when it is combined with Dactinomycin.Approved
DarifenacinThe metabolism of Erlotinib can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Erlotinib can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Erlotinib can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Erlotinib can be decreased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Erlotinib can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Erlotinib can be decreased when combined with Delavirdine.Approved
DesipramineThe serum concentration of Erlotinib can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Erlotinib.Approved
DesloratadineThe serum concentration of Erlotinib can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Erlotinib can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Erlotinib can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Erlotinib can be increased when it is combined with Diclofenac.Approved, Vet Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Erlotinib.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Erlotinib.Approved
DihydroergotamineThe metabolism of Erlotinib can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Erlotinib can be decreased when combined with Diltiazem.Approved
DiphenhydramineThe metabolism of Erlotinib can be decreased when combined with Diphenhydramine.Approved
DipyridamoleThe serum concentration of Erlotinib can be increased when it is combined with Dipyridamole.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Erlotinib.Approved, Investigational
DoxazosinThe serum concentration of Erlotinib can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Erlotinib can be decreased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Erlotinib can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Erlotinib can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Erlotinib can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Erlotinib can be decreased when combined with Dronedarone.Approved
DuloxetineThe metabolism of Erlotinib can be decreased when combined with Duloxetine.Approved
EfavirenzThe serum concentration of Erlotinib can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Erlotinib can be increased when it is combined with Elbasvir.Approved
EliglustatThe metabolism of Erlotinib can be decreased when combined with Eliglustat.Approved
EnalaprilThe serum concentration of Erlotinib can be increased when it is combined with Enalapril.Approved, Vet Approved
EnzalutamideThe serum concentration of Erlotinib can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Erlotinib can be decreased when it is combined with Epinastine.Approved, Investigational
ErgonovineThe serum concentration of Erlotinib can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Erlotinib can be increased when it is combined with Ergotamine.Approved
ErythromycinThe metabolism of Erlotinib can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Erlotinib can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe serum concentration of Erlotinib can be decreased when it is combined with Esomeprazole.Approved, Investigational
EstramustineThe serum concentration of Erlotinib can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Erlotinib can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Erlotinib can be decreased when it is combined with Estrone.Approved
EtoposideThe serum concentration of Erlotinib can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Erlotinib can be decreased when it is combined with Etravirine.Approved
FamotidineThe serum concentration of Erlotinib can be decreased when it is combined with Famotidine.Approved
FelodipineThe serum concentration of Erlotinib can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Erlotinib can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Erlotinib can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Erlotinib can be increased when it is combined with Fidaxomicin.Approved
FluconazoleThe metabolism of Erlotinib can be decreased when combined with Fluconazole.Approved
FluoxetineThe metabolism of Erlotinib can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Erlotinib can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Erlotinib can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Erlotinib can be increased when it is combined with Flurazepam.Approved, Illicit
FluvoxamineThe serum concentration of Erlotinib can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Erlotinib can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Erlotinib can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Erlotinib can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Erlotinib can be increased when it is combined with Fusidic Acid.Approved
GefitinibThe serum concentration of Erlotinib can be increased when it is combined with Gefitinib.Approved, Investigational
GemfibrozilThe metabolism of Erlotinib can be decreased when combined with Gemfibrozil.Approved
GenisteinThe serum concentration of Erlotinib can be increased when it is combined with Genistein.Investigational
GlyburideThe serum concentration of Erlotinib can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Erlotinib can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Erlotinib can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Erlotinib can be increased when it is combined with Grepafloxacin.Withdrawn
HaloperidolThe serum concentration of Erlotinib can be increased when it is combined with Haloperidol.Approved
HydrocortisoneThe serum concentration of Erlotinib can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
IdelalisibThe serum concentration of Erlotinib can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Erlotinib can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Erlotinib can be increased when it is combined with Imipramine.Approved
IndinavirThe serum concentration of Erlotinib can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Erlotinib can be increased when it is combined with Indomethacin.Approved, Investigational
IrbesartanThe metabolism of Erlotinib can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Erlotinib.Approved, Investigational
IsavuconazoniumThe metabolism of Erlotinib can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Erlotinib can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Erlotinib can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Erlotinib can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Erlotinib can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Erlotinib can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Erlotinib can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe serum concentration of Erlotinib can be increased when it is combined with Ketoconazole.Approved, Investigational
LansoprazoleThe serum concentration of Erlotinib can be decreased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Erlotinib can be increased when it is combined with Lapatinib.Approved, Investigational
LevofloxacinThe serum concentration of Erlotinib can be increased when it is combined with Levofloxacin.Approved, Investigational
LevothyroxineThe serum concentration of Erlotinib can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Erlotinib can be increased when it is combined with Lidocaine.Approved, Vet Approved
LiothyronineThe serum concentration of Erlotinib can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Erlotinib can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Erlotinib can be increased when it is combined with Lisinopril.Approved, Investigational
LomitapideThe serum concentration of Erlotinib can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Erlotinib can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Erlotinib can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Erlotinib can be increased when it is combined with Loratadine.Approved
LorcaserinThe metabolism of Erlotinib can be decreased when combined with Lorcaserin.Approved
LosartanThe serum concentration of Erlotinib can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Erlotinib can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Erlotinib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Erlotinib can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Erlotinib can be decreased when combined with Lumefantrine.Approved
MagaldrateThe serum concentration of Erlotinib can be decreased when it is combined with Magaldrate.Withdrawn
Magnesium carbonateThe serum concentration of Erlotinib can be decreased when it is combined with Magnesium carbonate.Approved
Magnesium hydroxideThe serum concentration of Erlotinib can be decreased when it is combined with Magnesium hydroxide.Approved
Magnesium oxideThe serum concentration of Erlotinib can be decreased when it is combined with Magnesium oxide.Approved
Magnesium TrisilicateThe serum concentration of Erlotinib can be decreased when it is combined with Magnesium Trisilicate.Approved
MaprotilineThe serum concentration of Erlotinib can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Erlotinib can be increased when it is combined with Mebendazole.Approved, Vet Approved
MefloquineThe serum concentration of Erlotinib can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Erlotinib can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeprobamateThe serum concentration of Erlotinib can be increased when it is combined with Meprobamate.Approved, Illicit
MethadoneThe serum concentration of Erlotinib can be increased when it is combined with Methadone.Approved
MethanthelineThe serum concentration of Erlotinib can be decreased when it is combined with Methantheline.Approved
MethotrimeprazineThe metabolism of Erlotinib can be decreased when combined with Methotrimeprazine.Approved
MetiamideThe serum concentration of Erlotinib can be decreased when it is combined with Metiamide.Experimental
MetoprololThe serum concentration of Erlotinib can be increased when it is combined with Metoprolol.Approved, Investigational
MexiletineThe metabolism of Erlotinib can be decreased when combined with Mexiletine.Approved
MibefradilThe serum concentration of Erlotinib can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Erlotinib can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Erlotinib can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Erlotinib can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe metabolism of Erlotinib can be decreased when combined with Mirabegron.Approved
MitomycinThe serum concentration of Erlotinib can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Erlotinib can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Erlotinib can be decreased when it is combined with Mitoxantrone.Approved, Investigational
ModafinilThe serum concentration of Erlotinib can be decreased when it is combined with Modafinil.Approved, Investigational
MorphineThe serum concentration of Erlotinib can be increased when it is combined with Morphine.Approved, Investigational
NafcillinThe serum concentration of Erlotinib can be decreased when it is combined with Nafcillin.Approved
NaltrexoneThe serum concentration of Erlotinib can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Erlotinib can be increased when it is combined with Naringenin.Experimental
NefazodoneThe serum concentration of Erlotinib can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Erlotinib can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Erlotinib can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Erlotinib can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Erlotinib can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Erlotinib can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Erlotinib can be decreased when it is combined with Nifedipine.Approved
NilotinibThe metabolism of Erlotinib can be decreased when combined with Nilotinib.Approved, Investigational
NisoldipineThe serum concentration of Erlotinib can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Erlotinib can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Erlotinib can be increased when it is combined with Nitrendipine.Approved
NizatidineThe serum concentration of Erlotinib can be decreased when it is combined with Nizatidine.Approved
NorethisteroneThe serum concentration of Erlotinib can be decreased when it is combined with Norethisterone.Approved
OlanzapineThe serum concentration of Erlotinib can be decreased when it is combined with Olanzapine.Approved, Investigational
OlaparibThe metabolism of Erlotinib can be decreased when combined with Olaparib.Approved
OmeprazoleThe serum concentration of Erlotinib can be decreased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Erlotinib can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Erlotinib.Approved
P-NitrophenolThe serum concentration of Erlotinib can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Erlotinib.Approved, Vet Approved
PalbociclibThe serum concentration of Erlotinib can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Erlotinib can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Erlotinib can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Erlotinib can be decreased when it is combined with Pantoprazole.Approved
ParoxetineThe metabolism of Erlotinib can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Erlotinib.Approved
Peginterferon alfa-2bThe serum concentration of Erlotinib can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentobarbitalThe serum concentration of Erlotinib can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerindoprilThe serum concentration of Erlotinib can be increased when it is combined with Perindopril.Approved
PhenobarbitalThe serum concentration of Erlotinib can be decreased when it is combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Erlotinib can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozideThe serum concentration of Erlotinib can be increased when it is combined with Pimozide.Approved
PioglitazoneThe metabolism of Erlotinib can be decreased when combined with Pioglitazone.Approved, Investigational
Platelet Activating FactorThe serum concentration of Erlotinib can be decreased when it is combined with Platelet Activating Factor.Experimental
PonatinibThe serum concentration of Erlotinib can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Erlotinib can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Erlotinib can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Erlotinib can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Erlotinib can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimidoneThe serum concentration of Erlotinib can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Erlotinib can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Erlotinib can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazineThe metabolism of Erlotinib can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe serum concentration of Erlotinib can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Erlotinib can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Erlotinib can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Erlotinib can be increased when it is combined with Protriptyline.Approved
QuercetinThe serum concentration of Erlotinib can be increased when it is combined with Quercetin.Experimental
QuinacrineThe serum concentration of Erlotinib can be increased when it is combined with Quinacrine.Approved
QuinidineThe metabolism of Erlotinib can be decreased when combined with Quinidine.Approved
QuinineThe serum concentration of Erlotinib can be increased when it is combined with Quinine.Approved
RabeprazoleThe serum concentration of Erlotinib can be decreased when it is combined with Rabeprazole.Approved, Investigational
RanitidineThe serum concentration of Erlotinib can be decreased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Erlotinib can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Erlotinib can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Erlotinib can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Erlotinib can be decreased when it is combined with Reserpine.Approved
RifabutinThe serum concentration of Erlotinib can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Erlotinib can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Erlotinib can be decreased when it is combined with Rifapentine.Approved
RilpivirineThe serum concentration of Erlotinib can be increased when it is combined with Rilpivirine.Approved
RitonavirThe serum concentration of Erlotinib can be increased when it is combined with Ritonavir.Approved, Investigational
RolapitantThe serum concentration of Erlotinib can be increased when it is combined with Rolapitant.Approved
RopiniroleThe metabolism of Erlotinib can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneThe metabolism of Erlotinib can be decreased when combined with Rosiglitazone.Approved, Investigational
Roxatidine acetateThe serum concentration of Erlotinib can be decreased when it is combined with Roxatidine acetate.Approved
SaquinavirThe serum concentration of Erlotinib can be increased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Erlotinib can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Erlotinib can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Erlotinib can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SertralineThe serum concentration of Erlotinib can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Erlotinib can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Erlotinib can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Erlotinib can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Erlotinib can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Erlotinib can be decreased when it is combined with Sirolimus.Approved, Investigational
SorafenibThe serum concentration of Erlotinib can be increased when it is combined with Sorafenib.Approved, Investigational
SpironolactoneThe serum concentration of Erlotinib can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Erlotinib can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Erlotinib can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Erlotinib can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Erlotinib can be decreased when it is combined with Streptozocin.Approved
SulfamethoxazoleThe metabolism of Erlotinib can be decreased when combined with Sulfamethoxazole.Approved
SulfinpyrazoneThe serum concentration of Erlotinib can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Erlotinib can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Erlotinib can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Erlotinib can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Erlotinib can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Erlotinib can be decreased when it is combined with Tacrolimus.Approved, Investigational
TAK-390MRThe serum concentration of Erlotinib can be decreased when it is combined with TAK-390MR.Investigational
TamoxifenThe serum concentration of Erlotinib can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Erlotinib can be increased when it is combined with Taurocholic Acid.Experimental
TelaprevirThe serum concentration of Erlotinib can be increased when it is combined with Telaprevir.Approved
TelithromycinThe serum concentration of Erlotinib can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Erlotinib can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Erlotinib can be increased when it is combined with Temsirolimus.Approved
TenofovirThe metabolism of Erlotinib can be decreased when combined with Tenofovir.Approved, Investigational
TerazosinThe serum concentration of Erlotinib can be increased when it is combined with Terazosin.Approved
TerbinafineThe metabolism of Erlotinib can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Erlotinib can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Erlotinib can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Erlotinib can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Erlotinib can be increased when it is combined with Testosterone.Approved, Investigational
TheophyllineThe metabolism of Erlotinib can be decreased when combined with Theophylline.Approved
ThioridazineThe metabolism of Erlotinib can be decreased when combined with Thioridazine.Approved
TicagrelorThe serum concentration of Erlotinib can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Erlotinib can be decreased when combined with Ticlopidine.Approved
TipranavirThe metabolism of Erlotinib can be decreased when combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Erlotinib can be decreased when it is combined with Tocilizumab.Approved
TolvaptanThe serum concentration of Erlotinib can be increased when it is combined with Tolvaptan.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Erlotinib.Approved, Investigational
TranylcypromineThe metabolism of Erlotinib can be decreased when combined with Tranylcypromine.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Erlotinib.Approved, Investigational
TrazodoneThe serum concentration of Erlotinib can be decreased when it is combined with Trazodone.Approved, Investigational
TrifluoperazineThe serum concentration of Erlotinib can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Erlotinib can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Erlotinib can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Erlotinib can be increased when it is combined with Trimipramine.Approved
TroleandomycinThe serum concentration of Erlotinib can be increased when it is combined with Troleandomycin.Approved
VemurafenibThe serum concentration of Erlotinib can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Erlotinib can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Erlotinib can be decreased when combined with Verapamil.Approved
VinblastineThe serum concentration of Erlotinib can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Erlotinib can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Erlotinib can be increased when it is combined with Vinorelbine.Approved, Investigational
VoriconazoleThe serum concentration of Erlotinib can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Erlotinib.Approved
ZimelidineThe serum concentration of Erlotinib can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Erlotinib can be decreased when combined with Ziprasidone.Approved
Food Interactions
  • Take at least 1 hour before or 2 hours after any food.
  • Take with a glass of water.
References
Synthesis Reference

DrugSyn.org

US5747498
General References
  1. Raymond E, Faivre S, Armand JP: Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs. 2000;60 Suppl 1:15-23; discussion 41-2. [PubMed:11129168 ]
  2. Li Z, Xu M, Xing S, Ho WT, Ishii T, Li Q, Fu X, Zhao ZJ: Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem. 2007 Feb 9;282(6):3428-32. Epub 2006 Dec 18. [PubMed:17178722 ]
  3. Dudek AZ, Kmak KL, Koopmeiners J, Keshtgarpour M: Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Lung Cancer. 2006 Jan;51(1):89-96. Epub 2005 Nov 14. [PubMed:16290256 ]
  4. Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE, Nicholson RI: Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer. 2004 Dec;11(4):793-814. [PubMed:15613453 ]
  5. Blum G, Gazit A, Levitzki A: Substrate competitive inhibitors of IGF-1 receptor kinase. Biochemistry. 2000 Dec 26;39(51):15705-12. [PubMed:11123895 ]
External Links
ATC CodesL01XE03
AHFS Codes
  • 10:00.00
PDB EntriesNot Available
FDA labelDownload (999 KB)
MSDSDownload (107 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9359
Blood Brain Barrier+0.9376
Caco-2 permeable+0.5737
P-glycoprotein substrateSubstrate0.5982
P-glycoprotein inhibitor IInhibitor0.5958
P-glycoprotein inhibitor IINon-inhibitor0.6169
Renal organic cation transporterNon-inhibitor0.7171
CYP450 2C9 substrateNon-substrate0.7942
CYP450 2D6 substrateNon-substrate0.7611
CYP450 3A4 substrateSubstrate0.5886
CYP450 1A2 substrateInhibitor0.7826
CYP450 2C9 inhibitorNon-inhibitor0.5739
CYP450 2D6 inhibitorNon-inhibitor0.6329
CYP450 2C19 inhibitorInhibitor0.598
CYP450 3A4 inhibitorInhibitor0.7194
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7911
Ames testAMES toxic0.5195
CarcinogenicityNon-carcinogens0.9551
BiodegradationNot ready biodegradable0.9907
Rat acute toxicity2.3958 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8158
hERG inhibition (predictor II)Non-inhibitor0.6776
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Osi pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
TabletOral100 mg/1
TabletOral100 mg
TabletOral150 mg
TabletOral150 mg/1
TabletOral25 mg/1
TabletOral25 mg
Tablet, film coatedOral100 mg
Tablet, film coatedOral150 mg
Tablet, film coatedOral25 mg
Prices
Unit descriptionCostUnit
Tarceva 150 mg tablet163.98USD tablet
Tarceva 100 mg tablet144.98USD tablet
Tarceva 25 mg tablet52.78USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2216796 No2003-09-022015-06-06Canada
CA2514977 No2010-06-222024-02-11Canada
US5747498 Yes1999-05-082019-05-08Us
US6900221 Yes2001-05-092021-05-09Us
US7087613 Yes2001-05-092021-05-09Us
USRE41065 Yes1999-05-082019-05-08Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityVery slightly soluble (hydrochloride salt - maximal solubility of approximately 0.4 mg/mL occurs at a pH of approximately 2)Not Available
logP2.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00891 mg/mLALOGPS
logP3.13ALOGPS
logP3.2ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)16.14ChemAxon
pKa (Strongest Basic)4.59ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area74.73 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity107.79 m3·mol-1ChemAxon
Polarizability43.48 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassNaphthyridines
Sub ClassQuinazolines
Direct ParentQuinazolinamines
Alternative Parents
Substituents
  • Quinazolinamine
  • Aminopyrimidine
  • Alkyl aryl ether
  • Imidolactam
  • Benzenoid
  • Pyrimidine
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Azacycle
  • Secondary amine
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Ubiquitin protein ligase binding
Specific Function:
Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on ke...
Gene Name:
EGFR
Uniprot ID:
P00533
Molecular Weight:
134276.185 Da
References
  1. Kim TE, Murren JR: Erlotinib OSI/Roche/Genentech. Curr Opin Investig Drugs. 2002 Sep;3(9):1385-95. [PubMed:12498017 ]
  2. Laird AD, Cherrington JM: Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Expert Opin Investig Drugs. 2003 Jan;12(1):51-64. [PubMed:12517254 ]
  3. Delbaldo C, Faivre S, Raymond E: [Epidermal growth factor inhibitors]. Rev Med Interne. 2003 Jun;24(6):372-83. [PubMed:12814826 ]
  4. Bulgaru AM, Mani S, Goel S, Perez-Soler R: Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase. Expert Rev Anticancer Ther. 2003 Jun;3(3):269-79. [PubMed:12820772 ]
  5. Akita RW, Sliwkowski MX: Preclinical studies with Erlotinib (Tarceva). Semin Oncol. 2003 Jun;30(3 Suppl 7):15-24. [PubMed:12840797 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism and secretion of potentially harmful xenobiotics, drugs and endogenous compounds. Activated by the antibiotic rifampicin and various plant metabolites, such as hyperforin, guggulipid, colupulone, and is...
Gene Name:
NR1I2
Uniprot ID:
O75469
Molecular Weight:
49761.245 Da
References
  1. Harmsen S, Meijerman I, Beijnen JH, Schellens JH: Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor. Cancer Chemother Pharmacol. 2009 Jun;64(1):35-43. doi: 10.1007/s00280-008-0842-3. Epub 2008 Oct 7. [PubMed:18839173 ]
  2. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976 ]
  2. Johnson JR, Cohen M, Sridhara R, Chen YF, Williams GM, Duan J, Gobburu J, Booth B, Benson K, Leighton J, Hsieh LS, Chidambaram N, Zimmerman P, Pazdur R: Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res. 2005 Sep 15;11(18):6414-21. [PubMed:16166415 ]
  3. Li J, Zhao M, He P, Hidalgo M, Baker SD: Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007 Jun 15;13(12):3731-7. [PubMed:17575239 ]
  4. Hamilton M, Wolf JL, Rusk J, Beard SE, Clark GM, Witt K, Cagnoni PJ: Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2166-71. [PubMed:16609030 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976 ]
  2. Li J, Zhao M, He P, Hidalgo M, Baker SD: Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007 Jun 15;13(12):3731-7. [PubMed:17575239 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976 ]
  2. Lu JF, Eppler SM, Wolf J, Hamilton M, Rakhit A, Bruno R, Lum BL: Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther. 2006 Aug;80(2):136-45. [PubMed:16890575 ]
  3. Johnson JR, Cohen M, Sridhara R, Chen YF, Williams GM, Duan J, Gobburu J, Booth B, Benson K, Leighton J, Hsieh LS, Chidambaram N, Zimmerman P, Pazdur R: Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res. 2005 Sep 15;11(18):6414-21. [PubMed:16166415 ]
  4. Li J, Zhao M, He P, Hidalgo M, Baker SD: Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007 Jun 15;13(12):3731-7. [PubMed:17575239 ]
  5. Hamilton M, Wolf JL, Rusk J, Beard SE, Clark GM, Witt K, Cagnoni PJ: Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2166-71. [PubMed:16609030 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976 ]
  2. Johnson JR, Cohen M, Sridhara R, Chen YF, Williams GM, Duan J, Gobburu J, Booth B, Benson K, Leighton J, Hsieh LS, Chidambaram N, Zimmerman P, Pazdur R: Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res. 2005 Sep 15;11(18):6414-21. [PubMed:16166415 ]
  3. Li J, Zhao M, He P, Hidalgo M, Baker SD: Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007 Jun 15;13(12):3731-7. [PubMed:17575239 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976 ]
  2. Li J, Zhao M, He P, Hidalgo M, Baker SD: Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007 Jun 15;13(12):3731-7. [PubMed:17575239 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976 ]
  2. Hamilton M, Wolf JL, Rusk J, Beard SE, Clark GM, Witt K, Cagnoni PJ: Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2166-71. [PubMed:16609030 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Molecular Weight:
60845.33 Da
References
  1. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976 ]
  2. Li J, Zhao M, He P, Hidalgo M, Baker SD: Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007 Jun 15;13(12):3731-7. [PubMed:17575239 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naph...
Gene Name:
UGT1A1
Uniprot ID:
P22309
Molecular Weight:
59590.91 Da
References
  1. Liu Y, Ramirez J, House L, Ratain MJ: The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation. Eur J Cancer. 2010 Jul;46(11):2097-103. doi: 10.1016/j.ejca.2010.04.022. Epub 2010 May 23. [PubMed:20580994 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y: Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci. 2009 Sep;100(9):1701-7. doi: 10.1111/j.1349-7006.2009.01213.x. Epub 2009 May 12. [PubMed:19493273 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MA, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH: Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther. 2008 Aug;7(8):2280-7. doi: 10.1158/1535-7163.MCT-07-2250. [PubMed:18723475 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 07, 2016 03:54